Do GLP-1 Patches Work? What the Evidence Says

Key takeaways

• No. No semaglutide or tirzepatide patch is approved in the United States; every version of both drugs in FDA's database is an injection or a tablet, and all need a prescription.
• Size is the reason. Skin lets through molecules under about 500 daltons; semaglutide weighs 4,114 and tirzepatide 4,814. Even the Wegovy tablet, built with an absorption enhancer, gets only 1 to 2 percent of its semaglutide into the blood.
• The 'GLP-1' patches, drops, gummies and sprays sold online are supplements with no GLP-1 drug in them, usually berberine and plant extracts, or unapproved drugs.
• Berberine is not a GLP-1 drug. Across 23 randomized trials of the swallowed supplement, it lowered weight by 0.88 kg more than control.
• Real GLP-1 patches are experimental: microneedle patches worked in rats and minipigs, and human trials began in 2026. What works today is a prescribed GLP-1, injected weekly or taken as a daily pill.

Do GLP-1 patches work? Not as a way to get a GLP-1 drug into your body. No semaglutide or tirzepatide patch has been approved in the United States, these molecules are far too large to cross intact skin in useful amounts, and the 'GLP-1 patches', drops, gummies and sprays sold online are either supplements that contain no GLP-1 drug, typically berberine and other plant extracts, or unapproved drugs. This page is the needle-free companion to our microdosing GLP-1 guide and to GLP-1 injection sites, for anyone whose real goal is a weekly shot that hurts less.

What is actually sold as a GLP-1 patch, drop or spray

Sources: (White 2026) (FDA drops letter 2024) (ClinicalTrials.gov NCT07673900) (Wegovy label). Compounding rules are in our legal tracker. FDA's Drugs@FDA database, searched October 10, 2026, lists semaglutide and tirzepatide only as injections and oral tablets.

Why a GLP-1 drug cannot get through your skin

The outer layer of skin exists to keep molecules out. In a widely cited analysis, two Amsterdam dermatologists argued that a compound must weigh under about 500 daltons to be absorbed through skin: virtually all contact allergens and every drug then used in a transdermal patch fall below that size, and larger molecules cannot pass the outer layer (Bos 2000). Nicotine and estrogen patches work because their drugs are small.

GLP-1 drugs are not. Semaglutide weighs 4,113.58 daltons (Wegovy label) and tirzepatide 4,813.53 (Zepbound label), eight to ten times the threshold. A team developing GLP-1 patches put it plainly: transdermal delivery of peptide drugs "is almost impossible" with conventional penetration enhancers (Lin 2025).

The gut shows how hard the problem is. Injected semaglutide is 89 percent bioavailable. The Wegovy tablet carries an absorption enhancer (SNAC) and still delivers only about 1 to 2 percent of its semaglutide to the blood, which is why the tablet dose is 25 mg a day against 2.4 mg a week by injection; the label says not to split, crush, chew or dissolve it (Wegovy label). If the manufacturer needs an engineered enhancer and about 70 times more drug per week to cross the stomach lining, a sticker on the arm, with neither and usually no semaglutide at all, will not cross the skin.

One nuance: berberine, the most common patch ingredient, weighs about 336 daltons (PubChem), so size does not rule it out. But we found no trial of a berberine skin patch for weight loss in PubMed.

What the transdermal GLP-1 research shows

Scientists are working on GLP-1 patches, and every result so far is experimental.

A passive patch, in mice. In a 2025 study, 18 male mice on a high-fat diet received, for seven weeks, a placebo injection, a weekly 10-microgram semaglutide injection, or a patch holding 2 mg of semaglutide applied for 8 hours a week to back skin with the hair removed. Both semaglutide groups lost weight compared with placebo, and the authors reported larger effects with the patch (Li 2025). The patch carried 200 times the injected dose, on depilated rodent skin, and the paper does not report how much drug reached the blood.

Microneedle patches. These pierce the outer layer with microscopic needles that dissolve and release the drug, which makes them a needle-free injection rather than a patch that crosses intact skin. One design delivered up to 0.93 mg of liraglutide, an older GLP-1 drug, from a 0.9 cm² patch; relative to injection, 69.8 percent reached the blood in rats and 46.3 percent in minipigs, with mild redness after a week of daily use at one site in the pigs (Lin 2025).

The first human trials. ClinicalTrials.gov lists two phase 1 trials of semaglutide microneedle patches, both recruiting when we checked on October 10, 2026: a first-in-human US study comparing the patch with injection in an estimated 62 healthy adults with overweight or obesity, with primary completion due in February 2027 (ClinicalTrials.gov NCT07673900), and a South Korean study measuring blood levels in an estimated 72 healthy adults (NCT07539415). Phase 1 trials test safety and absorption, not weight loss. A successful product would still need larger trials and FDA approval, and it would be a prescription drug.

What is inside the supplement patches, and what it does

University of Connecticut pharmacists identified 24 patches and one gel sold as 'natural GLP-1' supplements. They averaged seven ingredients, most often berberine, glutamine or glutamate, cinnamon and pomegranate. None posted a certificate of analysis, many lacked the FDA disclaimer required on supplement claims, many used deceptive advertising, and several carried one- and two-star reviews describing no effect or side effects. The authors add a legal point: federal law defines dietary supplements as products taken by mouth, so a patch cannot lawfully be one (White 2026).

Berberine is a plant alkaloid, not a GLP-1 receptor agonist, whatever the label says about 'activating' GLP-1. Its human evidence comes from swallowed supplements: a 2026 meta-analysis of 23 randomized trials found weight fell 0.88 kg more than with control (95% confidence interval 0.39 to 1.36 kg) and BMI 0.48 points more, with a small drop in waist circumference. The authors called for better reporting of purity, potency and dose (Elahi Vahed 2026). For scale, the semaglutide tablet produced 13.6 percent weight loss against 2.4 percent on placebo over 64 weeks (Wegovy label), about 12 kg more than placebo at the trial's average starting weight of 106 kg.

What FDA has done

The one FDA warning letter we have read that names a non-injectable 'GLP-1' product concerned drops. In December 2024, FDA wrote to an online seller of 'metabolic boost drops' whose website claimed clinical-trial weight loss, invoked 'the science of GLP-1' and showed an 'FDA approved' badge. FDA called the drops unapproved new drugs, and misbranded because the labeling was false or misleading (FDA drops letter 2024).

FDA has now named a patch. Among seven warning letters dated March 31, 2026 and posted April 7, one went to an eBay seller of a 'semaglutide nano microneedle patch' and another to an eBay seller of an oral 'GLP-1 weight control' solution; the other five went to research-peptide websites selling semaglutide, tirzepatide and retatrutide vials (Policy Canary 2026). The August 24, 2026 letters concerned more research-labeled peptides, and 55 letters went to telehealth companies over compounded GLP-1 marketing (legal tracker). We have not seen a letter naming a GLP-1 spray, which reflects where enforcement has focused, not that sprays are lawful.

How to spot the marketing

• 'GLP-1 activation', 'GLP-1 booster', 'supports natural GLP-1'. Supplement language for a product with no GLP-1 drug in it.
• 'Ozempic in a patch', 'semaglutide without needles'. No approved product fits. A patch that really contained semaglutide would be an untested, unapproved drug.
• 'FDA approved' or 'clinically proven' with no trial named. FDA does not approve supplements. If a study is cited, check whether it was in mice or used berberine capsules.
• No prescription, clinician or pharmacy. Every approved GLP-1 is prescription only.
• No certificate of analysis. The 2026 survey found none for any patch (White 2026).

What works instead

The GLP-1s with trial evidence are prescription drugs. Weekly semaglutide (Wegovy) and tirzepatide (Zepbound) injections are the most studied; if the needle is the obstacle, GLP-1 injection sites covers how to make the shot close to painless. The Wegovy tablet, approved in December 2025, starts at 1.5 mg a day and climbs every 30 days to 25 mg, taken on an empty stomach (Wegovy label); the semaglutide dosage chart has the schedule, and our cost guide lists it at $149 to $299 a month for cash payers. Rybelsus is oral semaglutide for type 2 diabetes, and Foundayo (orforglipron), approved in 2026, is a daily weight-loss pill that is not a peptide. Compounded vials are legal only in narrow circumstances, set out in our compounded semaglutide versus tirzepatide guide; if you are prescribed one, check each dose in units with the peptide calculator.

Bottom line

A sticker cannot push a GLP-1 drug through intact skin. What is sold as a GLP-1 patch, drop, gummy or spray is a berberine-and-botanicals supplement, worth under a kilogram even when swallowed, or an unapproved drug no one has verified. Microneedle semaglutide patches are real science, in phase 1 trials. Until one is approved, the needle-free GLP-1 is a prescribed pill.

Frequently asked questions

+−Do GLP-1 patches work?

Not as a way to take a GLP-1 drug. No semaglutide or tirzepatide patch is approved in the United States, and the molecules weigh about 4,100 and 4,800 daltons, eight to ten times the size that passes through intact skin. The 'natural GLP-1' patches sold online contain no GLP-1 drug: a 2026 survey of 24 of them found an average of seven botanical and nutrient ingredients, most often berberine, glutamine, cinnamon and pomegranate, and no certificates of analysis. None has a published trial showing weight loss.

+−Are there semaglutide patches?

Not approved ones. Every semaglutide product in FDA's drug database is an injection or a tablet. Two phase 1 trials of semaglutide microneedle patches, which pierce the outer layer of skin with tiny dissolving needles, began recruiting in 2026 in the United States and South Korea; they measure safety and blood levels, not weight loss, and have no results yet. A patch sold today as containing semaglutide is either a supplement that does not or an unapproved drug that no one has tested.

+−Do GLP-1 drops work?

Drops sold as GLP-1 supplements contain no GLP-1 drug, and none has a trial. In December 2024 FDA warned a seller of 'metabolic boost drops' that advertised 'the science of GLP-1', a clinical trial and an 'FDA approved' badge, calling them unapproved and misbranded drugs. Compounded semaglutide drops taken under the tongue do contain the drug but have no published trial, and the approved semaglutide pill needs a built-in absorption enhancer to reach 1 to 2 percent absorption; its label says not to crush or dissolve it.

+−Can you trust GLP-1 drops reviews?

Reviews are not evidence of what a product contains or does. Reviews on a seller's own site cannot be checked, and the independent ones point the other way: the 2026 survey of 'natural GLP-1' patches found several products with one- or two-star ratings and comments describing no effect or side effects. Ask for a trial and an FDA approval instead; for these products neither exists.

+−Do GLP-1 support supplements work?

Modestly at best, and not like a GLP-1 drug. 'Supports GLP-1' is marketing language for a supplement that contains no GLP-1 drug. The most common active ingredient, berberine, has been tested in randomized trials as a swallowed supplement: across 23 trials it lowered body weight by an average of 0.88 kg compared with control. For comparison, the semaglutide tablet produced about 12 kg more weight loss than placebo over 64 weeks for an average participant in its trial.

+−Is berberine a natural GLP-1?

No. Berberine is a plant alkaloid, not a GLP-1 receptor agonist and not a GLP-1 drug, whatever the label says about 'activating' GLP-1. Its weight effect in a 2026 meta-analysis of 23 trials was under 1 kg, and the authors flagged poor reporting of the supplements' purity, potency and dose. It is small enough to cross skin, but we found no trial of a berberine skin patch for weight loss.

+−Is there a GLP-1 that is not an injection?

Yes, by prescription. The Wegovy tablet, approved in December 2025, is semaglutide 25 mg taken once daily after a monthly dose climb; in its 64-week trial it produced 13.6 percent weight loss against 2.4 percent on placebo. Rybelsus is oral semaglutide for type 2 diabetes, and Foundayo (orforglipron), approved in 2026, is a daily pill that is not a peptide at all. None of them is a patch, a drop or a supplement.

Sources

1. ReviewBos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000;9:165-9. (2000)
2. LabelNovo Nordisk. Wegovy (semaglutide) injection and tablets: prescribing information, revised June 2026, sections 2 (tablet administration), 11 (molecular weight), 12.3 (bioavailability of injection and tablets) and 14 (Study 7, the 64-week tablet trial) (DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b). (2026)
3. StudyLi W et al. Transdermal semaglutide administration in mice: reduces body weight by suppressing appetite and enhancing metabolic rate. Biology (Basel) 2025;14:575. (2025)
4. StudyLin H et al. Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs. Drug Deliv Transl Res 2025;15:216-30. (2025)
5. SourceClinicalTrials.gov. NCT07673900: randomized phase 1, first-in-human study of semaglutide delivered by microneedle array patch versus subcutaneous injection in healthy adults with overweight or obesity (estimated 62 participants; started June 15, 2026; primary completion February 2027). Record accessed October 10, 2026. (2026)
6. StudyWhite CM, Tai Z, Nuzi K. Transdermal 'natural GLP-1' dietary supplements violate law and place patients at risk. Ann Pharmacother 2026;60:813-6. (2026)
7. ReviewElahi Vahed I et al. The effect of berberine on obesity indices: a systematic review and meta-analysis. Int J Obes (Lond) 2026;50:53-73. (2026)
8. NewsPolicy Canary. The research use only loophole just closed: FDA hits seven peptide websites in a single day (warning letters dated March 31, 2026, including an eBay seller of a semaglutide microneedle patch). April 21, 2026. (2026)
9. RegulatoryFDA. Warning letter 694688 to an online seller of 'metabolic boost drops' promoted with GLP-1 science, clinical-trial and 'FDA approved' claims (unapproved new drugs; misbranding). December 10, 2024. (2024)